Avenue Therapeutics (NASDAQ:ATXI) Vs. BPTS, AADI, AGRX, GANX, AKTX, MITO, DMAC, ELDN, ARAV, and ADIL
Should you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Biophytis (BPTS), Aadi Bioscience (AADI), Agile Therapeutics (AGRX), Gain Therapeutics (GANX), Akari Therapeutics (AKTX), Stealth BioTherapeutics (MITO), DiaMedica Therapeutics (DMAC), Eledon Pharmaceuticals (ELDN), Aravive (ARAV), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical preparations" industry.
Avenue Therapeutics vs.
Avenue Therapeutics (NASDAQ:ATXI) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
Avenue Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 376.19%. Aadi Bioscience has a consensus price target of $47.67, indicating a potential upside of 81.73%. Given Avenue Therapeutics' higher probable upside, equities research analysts clearly believe Avenue Therapeutics is more favorable than Aadi Bioscience.
Aadi Bioscience has higher revenue and earnings than Avenue Therapeutics.
In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Aadi Bioscience's average media sentiment score.
Avenue Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.
Avenue Therapeutics received 140 more outperform votes than Aadi Bioscience when rated by MarketBeat users. However, 100.00% of users gave Aadi Bioscience an outperform vote while only 60.00% of users gave Avenue Therapeutics an outperform vote.
Aadi Bioscience's return on equity of -42.00% beat Avenue Therapeutics' return on equity.
6.7% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 51.9% of Aadi Bioscience shares are owned by institutional investors. 4.0% of Avenue Therapeutics shares are owned by insiders. Comparatively, 7.1% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Aadi Bioscience beats Avenue Therapeutics on 10 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip ChartAvenue Therapeutics (NASDAQ:ATXI) vs. Its Competitors
Avenue Therapeutics Competitors List
